Target ALS is proud to announce that three consortia have been selected for awards through our Biomarker Consortia Program. As new therapeutics begin moving the needle for people with ALS, the field ...

The Target ALS Global Natural History Study (GNHS) is entering a new phase of discovery. As the only international, longitudinal study generating deeply characterized clinical, genomic, and biofluid ...

Today, we mourn the loss of Brooke Eby. Brooke was a powerhouse. Witty, clever, joyful, and direct. She was unwilling to be silenced by ALS. To take a fatal diagnosis at 33 and find humor in it, and ...

Whether you’re newly diagnosed, living with ALS, or caring for someone who is, you don’t have to navigate this alone. This resource center brings together trusted information from experts in the field ...

Michael R. DeChellis-Marks, Ph.D., joined Target ALS in 2025 as Manager of Scientific Programs, where he monitors the Target ALS scientific portfolio, curates and coordinates funding calls, and ...

A biomarker is a measurable signal in the body that gives researchers clues about what’s happening inside. It might be a substance in the blood like cholesterol, or a physiological measure like blood ...

Target ALS is proud to announce a powerful new resource for ALS researchers: a collection of 28 standardized, well-characterized, and accessible fibroblast-derived induced pluripotent stem cell (iPSC) ...

Target ALS is proud to announce the newest projects selected through our In Vivo Target Validation Program, an initiative designed to accelerate promising ALS therapeutics toward clinical development.

ALS is a disease of the motor neurons. However, emerging research from Target ALS-funded scientists is revealing that it’s not that simple; there’s a complex breakdown involving the immune system, ...

In the first quarter of 2026, researchers across the Target ALS innovation ecosystem published more than 30 peer-reviewed papers, spanning biomarkers, disease mechanisms, therapeutic targets, and more ...

At the end of 2025, Target ALS accepted letters of intent (LOIs) from consortia with the goal of investigating the underlying disease biology of ALS. Consortia groups were invited to submit full ...